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Abstract
Background: On behalf of the medical staff of the National Institute of Oncology of Rabat, we conducted a
retrospective study to report epidemiology and 5-year outcomes of cervical carcinoma in Moroccan women.
Methods: We reviewed all women diagnosed with invasive cervical carcinoma in our institute between January
2006 and December 2006. Outcomes and prognoses are analyzed in patients who received at least one treatment.
Results: The analysis included 646 women. Median age was 50 years (23–85 years). Bleeding was the most
frequent symptom (95 %). The most predominant histology was squamous cell carcinoma (94 %). The majority of
patients were diagnosed at locally advanced stages (88 %). Among patients who received treatment (n = 550), the
management was based on concurrent chemoradiotherapy in 69.7 % of cases. The median duration of follow-up
was 60 months (range 2–78 months). Overall survival, progression free survival, and locoregional recurrence free
survival were 63.2, 60.7 and 79.1 % respectively. Significant poor prognostic factors in univariate analysis included
stage, tumor size, lymph node involvement, anemia and absence of response to radiotherapy. The prognostic
significance of response to radiotherapy and stage were retained in multivariate analysis.
Conclusion: Cervical cancer in our Institute is diagnosed at locally advanced stages. Two third of patients were
treated by concurrent chemoradiotherapy. Outcome of Moroccan patients are comparable to that of western
countries. Significant prognostic factors were stage, tumor size, lymph node involvement, anemia, and response to
radiotherapy. The way to reduce the global burden of cervical cancer in our country continues to be the
development of vaccination and screening programs.
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Background
Cervical cancer is the third most common cancer and
the fourth leading cause of cancer death in females in
the world, accounting for 9 % (529,800) of the new can-
cer cases and 8 % (275,100) of the cancer deaths among
females in 2008 [1, 2]. Its incidence has remarkably de-
creased in western countries through organized screen-
ing programs [3]. However, in Africa, in general, and in
Morocco especially, cervical cancer represents a major
health problem and the leading cause of cancer death in
women because of the diagnosis at advanced stages [1].
In Moroccan women, cervical cancer is the second most
common cancer after breast cancer [4]. The incidences
of cervical cancer in Casablanca and Rabat were 14.4/
100000 (new cases per 100000 women) and 13/100000,
respectively.
The aim of our study was to assessing the current out-
comes after a diagnosis of cervical cancer since 2005
when campaigns to improve prevention and treatment
were launched by the efforts of the government and of
the Lalla Salma Foundation Prevention and Treatment
of Cancers. In a previous investigation of cervical cancer
in young Moroccan women, treated between 1980 and
1990,overall survival rate was only 41 % at 5 years [5].
Our hypothesis is that the outcomes of cervical cancer
were improved as compared to previous data.
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We retrospectively investigated women of all ages
withsquamous-cell carcinoma, adenocarcinoma, or ade-
nosquamous carcinoma of the cervix of International Fed-
eration of Gynecology and Obstetrics (FIGO 2002) stages
I, stage II, stage III of stage IV (Additional file 1, page 1).
Women were excluded from the study if they met any of
the following criteria: lack of pathological confirmation of
invasive carcinoma; and in situ cervical cancers.
All women diagnosed with invasive cervical carcin-
oma, between January 2006 and December 2006, were
included. In 2006, Morocco had only two cancer centers,
the most important was National Institute of Oncology
of Rabat which includes mainly patients coming from
northern and eastern regions of Morocco, the second
was Casablanca cancer center which include mainly
patients coming from southern regions of Morocco. So
the population included in our series is representative of
the general population of our country.
The ethical approval for the study was obtained from
our ethics committee; the National Institute of Oncology
ethics committee. Written informed consent was not re-
quired, however all patients provided there oral consent.
The ethics committee approved the verbal informed
consent procedure.
Patient’s medical records were reviewed for investigations
of demographic characteristics, clinical signs, clinical sage,
histological results, and outcomes. Biological work-ups
were analyzed. Radiological reports were reviewed to deter-
mine the stage of the disease caused by the invasive carcin-
oma. Data concerning treatment modalities, CCRT, RT,
Surgery, adjuvant treatments (CCRT, RT, brachytherapy),
preoperative treatments, and palliative treatments (radio-
therapy and chemotherapy), were collected and analyzed.
During radiotherapy treatment, patients were evalu-
ated weekly by clinical examination. During concurrent
chemo-radiotherapy, patients were evaluated weekly by
clinical examination, a complete blood count and serum
levels ofcreatinine. Patients had a pelvic examination
under anesthesia at the time of each intra-cavity treat-
ment (brachytherapy). During palliative, neo-adjuvant or
adjuvant chemotherapy, patients were evaluated every 3
weekly by clinical examination, complete blood count
and serum levels of creatinine. Once the treatment
ended, patients were evaluated every 3 months for the
first 2 years, every 6 months during the third, fourth and
fifth years, and then annually. Disease status was
assessed by history taking, physical examination, and
appropriate laboratory and radiologic tests. Safety was
assessed at the time of each evaluation with the use
Cooperative Group Common Toxicity Criteria.
We analyzed the outcome of patients treated in our
institute and the impact of certain prognostic factors on
survival: stage of the disease, tumor size, lymph node in-
volvement, anemia, and response to radiotherapy. These
factors were chosen because they affect the survival of
patients diagnosed with cervical carcinoma.
Statistical analysis
Loco-regional recurrence free survival (LRRFS) (locore-
gional events occurred in the cervix and/or regional
lymph nodes, with or without concurrent metastatic
recurrence) was calculated from the date of diagnosis
(biopsy) to the date of first documented locoregional
relapse. Progression free survival (PFS) was calculated
from the date of diagnosis (biopsy) tothe date of the first
physical or radiographic evidence of disease progression,
death or the last follow-up visit. Overall survival (OS)
was calculated from the date of diagnosis (biopsy) to the
date of death or the last follow-up visit. Kaplan-Meier
method was used to estimate the rates of 5 years LRRFS,
PFS, and OS. Log-rank-test was used to evaluate the
differences between the groups [6].
Univariate and multivariate Cox proportional hazard
regression models analyses were used to evaluate the
relationship between survival (LRRFS, PFS, and OS), and
prognostic factors (age, histology, stage of disease, lymph
node involvement, tumor volume, response to treat-
ment, and anemia) [7]. Candidate prognostic factors for
LRRFS, PFS, and OS, with a 0.5 level of significance in
univariate analysis were entered in a multivariate Cox
model. Statistical evaluation was carried out using SPSS
17.0 statistical software.
Patients lost to follow up before to receive at least one
treatment modality [CCRT, exclusive RT, Surgery, brachy-
therapy, and palliative treatments (radiotherapy and
chemotherapy)] were excluded from efficacy and safety
analyses (96 women). Patients lost to follow up during the
treatment or the follow up period were censored.
Study endpoints
The study endpoints include: the analysis of epidemio-
logical characteristics, evaluation of 5-year outcomes
(loco-regional control, progression free survival, and
overall survival), and analysis of prognostic factors.
Treatment of cancers in Morocco has significantly
evolved the last decade through the efforts of the
government and of the Lalla Salma Foundation Prevention
and Treatment of Cancers. Our hypothesis is that the
outcomes of patients with cervical cancer were improved.
Results
From January 2006 to December 2006, 646 patients were
enrolled. All of them were included in the epidemio-
logical analyzes of demographic and clinical characteris-
tics. Patients who did not receive any treatment were
excluded from efficacy and safety analyses.
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Patient and tumor characteristics (Tables 1 and 2)
Median age was 50 years (range 23–85 years). Median
duration of evolution of symptoms (from onset of symp-
toms to consultation at our center) was 5 months (range:
1–48 months). Bleeding was the most common symptom
showed in 95 % of cases, followed by leukorrhea (50.2 %).
Squamous cell carcinoma (SCC) histology was the
most common pathological type and was reported in
94 % of cases followed by adenocarcinoma in 5.5 % of
cases. Only 0.5 % of cases have adenosquamous carcin-
oma. Tumor size was equal or greater than 4 cm in 81 %
of cases with a median tumor size of 7 cm. Patients have
locally advanced stages (IB2, II, III and IV), according to
FIGO 2002 staging system, in 88 % of the cases. External
iliac, internal iliac and para-aortic lymph nodes were
observed in 96 cases (15 %), 70 cases (10.8 %), and 45
cases (7 %), respectively, and they were most often as-
sociated. Only fourteen patients were metastatic at
presentation (2.2 %).
Treatment modalities (Fig. 1) (n = 550)
Among 646 patients, the treatment has not been
done in 96 cases (14.6 %). These patients were lost to
follow-up before the initiation of management and
were excluded from efficacy analyses. This is largely
explained by the socio-economic level, often poor in
our population.
Three hundred eighty three patients (69.7 %) under-
went curative CCRT. Among these patients, 17 received
adjuvant surgery. Seven cases have complete patho-
logical response in surgical specimens. Exclusive radio-
therapy was indicated in 49 patients (8.9 %), only one
patient received adjuvant surgery (staged IIA with a size
of 3.5 cm). After EBRT (CCRT or exclusive RT, n = 432),
310 (72 %) patients received utero-vaginal brachyther-
apy, 56 cases (13 %) received external four fields RT at a
dose of 24 Gy and 18 (4 %) received adjuvant surgery.
Table 1 Demographic characteristics for all patients included
(n = 646)





15–24 years 1 (0.2 %)
25–34 years 41 (6.3 %)
35–44 years 172 (26.6 %)
45–54 years 197 (30.5 %)
55–64 years 136 (21.1 %)
65–74 years 73 (11.3 %)
> 75 years 26 (4 %)
Menopausalstatus
Menopausal 343 (53 %)
Premenopausal 303 (47 %)
Marital status
Single 33 (5 %)
Maried 517 (80 %)
ND 96 (15 %)
Age at first marriage
< 20 years 381 (59 %)
> 20 years 265 (41 %)
Number of parities
0 27 (4.2 %)
< 4 178 (27.5 %)
> =4 407 (63 %)
ND 34 (5.3 %)
Abreviations: ND not defined
Table 2 Findings on clinical examination
Clinical examination Number of patients (%)
Performance status
PS 1 530 (82 %)
PS 2 110 (17 %)
PS 3 6 (1 %)
Tumor size
< 4 cm 72 (11 %)
≥ 4 cm 574 (89 %)
State of the vagina
Not invaded 133 (20.6 %)
Invaded 513 (79.4 %)
Upper third 263 (40.7 %)
Middle third 196 (30.3 %)
Lower third 54 (8.4 %)
State of parameters
Not invaded 137 (21.2 %)
Invaded 509 (78.8 %)
Proximal 86 (13.3 %)
Distal 161 (25 %)
Until the wall 262 (40.5 %)
Clinical stage
IA 1 (0.1 %)
IB1 63 (9.8 %)
IB2 24 (3.7 %)
IIA 40 (6.3 %)
IIB 235 (36.5 %)
IIIA 3 (0.4 %)
IIIB 252 (39 %)
IVA 13 (2 %)
IVB 14 (2.2 %)
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Unfortunately, 48 patients (11 %) did not receive comple-
mentary treatment. Three hundred thirteen patients
presented with stage IIB distal or IIIB, 213 among them
received a complementary parametrial dose (9 Gy [3 × 3Gy]
or 10 Gy [5 × 2 Gy]), 46 patients received four additional
radiation fields at a dose of 24 Gy (2 Gy per fraction), and
54 patients did not receive complementary parametrial
dose. Among 137 patients who had suspicious pelvic lymph
node on imaging, 102 received complementary dose of RT,
while 35 patients did not receive lymph node complemen-
tary dose. Nine of 10 patients who have para-aortic lymph
node received a complementary dose of 10–10.8 Gy
(1.8-2Gy per fraction). A total of 81 patients did not
complete their treatment (lost to follow up).
Surgery was the initial treatment of 89 cases (16.3 %),
68 of them (85 %) received adjuvant treatment: CCRT in
41 cases, RT in 22 cases, and brachytherapy in 5 cases.
Twelve cases received preoperative brachytherapy
followed by surgery (2.1 %), 1 of them received adjuvant
RT, and 2 patient received adjuvant CCRT.
Neoadjuvant chemotherapy was not a standard treat-
ment in our institution, and was indicated in only 20
patients. Adjuvant chemotherapy was administered in
2 patients; in one case after surgery (stage IB1), and in a
second case after RT (stage IIA).
Palliatives treatments were administered in 17 patients
and were based on palliative RT in 12 cases and palliative
RT plus palliative CT in 5 cases.
Toxicities
Table 3 shows the frequency of acute toxicities poten-
tially associated with CCRT. Gade 3 and 4 anemia and
neutropenia were observed in 8.3 and 4 %, respectively.
Renal failure was showed in only 0.5 % of cases.
Outcomes
Patients who received at least one treatment (n = 550)
were included in the efficacy analysis.
Response to treatments
Table 4 shows the response to treatments at 3-months.
Overall survival
At 60 months median follow up, 160 deaths had been
reported. The probability of 5 year overall survival was
63.2 % (Fig. 2a).
Progression free survival
At 60 months median follow-up, 175 patients developed
recurrence, local recurrence in 22.7 % of the cases (n = 125)
and metastatic recurrence in 13.8 % of the cases (n = 74)
(bone metastases in 26 cases [35.1 %], lung in 13 cases
[17.5 %], peritoneal in 10 cases [13.5 %] and hepatic in 9
cases [12.2 %]). The probabilities of LRRFS and PFS at
5 years were 79.1, and 60.7 %, respectively (Fig. 2b and c).
Fig. 1 Treatments modalities
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Locoregional recurrences
Locoregional recurrences occurred in 22.7 % of the
cases, and metastasis recurrence occurred in 13.8 % of
the cases. Locoregional recurrences were associated with
metastatic evolution in 4.3 % of cases. 82.9 % of relapses
occurred in the first 2 years after treatment and 63.4 %
of recurrences are centro-pelvic.
Prognostic factors
In univariate analysis (Fig. 3 [a to o]), we identified five
poor prognostic factors with a statistically significant im-
pact on the disease: tumor size, clinical stage, lymph
node involvement, hemoglobin level less than 12 g/dl
during RT, and absence of response to radiotherapy
(46 Gy). Tumor size (greater than 4 cm) was a poor
prognostic factor that affected significantly OS (p < 0.0001),
PFS (p <0.0001) and LRRFS (p = 0.013). Clinical stage: Clin-
ical stage affected significantly the prognosis of our patients:
OS (p < 0.0001), PFS (p < 0.0001) and LRRFS (p = 0.007).
Lymph node involvement (suspected on imaging) was
a statistically poor prognostic factor influencing OS
(p = 0.008), PFS (p = 0.038) and LRRFS (p = 0.008).
Anemia during RT affected all parameters of survival:
OS (p = 0.016), PFS (p = 0.008) and LRRFS (p = 0.009).
Absence of response after a dose of 46 Gy of RT
influencing OS (p < 0.0001), PFS (p <0.0001) and
LRRFS (p = 0.075).
Multivariate analysis performed by using cox propor-
tional hazard model showed that response to RT and
clinical stage are two independent factors influencing
outcome of patients with cervical carcinoma in our
population. Absence of response to RT was a prognos-
tic factor influencing significantly and independently
PFS (p = 0.001) and OS (p = 0.001). Clinical stage was a
Table 3 Acute toxicities in patients treated with CCRT (n = 425)
Number of patients Percent
Anemia
Grade 1 113 26.6 %
Grade 2 78 18.3 %
Grade 3 31 7.3 %
Grade 4 4 1 %
Neutropenia
Grade 1 51 12 %
Grade 2 21 5 %
Grade 3 28 6.5 %
Grade 4 2 0.5 %
Renal failure 2 0.5 %
Table 4 Response to treatments at 3-months
Treatment Response
Surgery first (n = 89) R0 resection (93.2 %)




Unknown response (2.5 %)




CCRT Concurrent chemoradiotherapy, ORR Objective response rate, CR
complete response, PR Partialresponse, PD Progression disease,
RT radiotherapy
Fig. 2 Survival curves. Figure 1a: Overall survival; Fig. 1b:
Locoregional recurrence free survival; Fig. 1c: Progression
free survival
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prognostic factor affecting LRRFS (p = 0.09), PFS (p =
0.033) and OS (p = 0.012).
Discussion
We conducted a retrospecive study to evaluate the
epidemiology and outcome of cervical carcinoma in
Morocco. To our best knowledge, our study was the first
published study evaluating the epidemiological charac-
teristics and prognostic of cervical cancer in our
country. We found the predominance of locally
advanced stages, so the diagnosis was most often made
at advanced stages in 88 % of cases (IB2, II, III and IV in
3.7 %, 6.3 %, 36.9 %, 39 %, 2 % respectively). The major-
ity of patients (69.7 %) received CCRT. At 5 years, PFS
and OS were 63.2 and 60.7 % respectively. Outcomes of
our patients with cervical carcinoma are influenced by
response to RT and clinical stage who are two independ-
ent factors retained in multivariate analysis. After RT,
Fig. 3 Prognostic factors. Overall survival, Loco regional recurrence free survival, and progression free survival curves according to prognostic
factors. (4a, 4b, 4c): Tumor size; (4d, 4e, 4f): Clinical stage; (4 g, 4 h, 4i): Lymph node involvement; (4j, 4 k, 4 l): Hemoglobin level less than 12 g/dl
during radiotherapy; (3 M, 3 N, 3O): Tumor response to radiotherapy
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patients with clinical response to radiotherapy had a
higher rate of PFS and OS.
One potential drawback of our study was the high
number of lost to follow up patients before manage-
ment. The inclusion of these women may have affected
the overall survival from cervical cancer. This is due to
low socio-economic level of most cases included in our
institute. These patients have been excluded from the
efficacy analyses. In addition, we showed a high rate of
locoregional recurrences (22.7 %) which may be due
mainly to the delay of diagnosis, and secondarily due to
the quality of treatments received; surgery, lymph node
dissection, radiotherapy, spreading of radiation which is
very large in most cases (median 84 days), and radiation
- brachytherapy period which exceeded 6 weeks in all
cases. Among the strength of our study : the large sam-
ple size and the standardized treatments available in our
institute (surgery and or radiotherapy with or withouth
chemotherapy and brachytherapy).
Our results have shown that cervical cancer in
Morocco is diagnosed at advanced stages in 88 % of the
cases. Several retrospective studies have shown similar
findings. In South American population (n = 190), stage
distribution was the following: II and IIIB in 93.7 % of
cases. [8]. In the Korean series [9], we noted 43.8 % of
locally advanced stages IB2-IV. However, in Europe, cer-
vical cancer, was diagnosed mainly at localized stages IB;
73.4 % in France [10]. In an Asiatic series from investiga-
tor in Beijing (n = 1399) [11], there is a predominance of
localized stage I in 57.1 %. The discrepancy noted in the
results of different series is due to socio-economic level
on one hand and practice in another hand. Indeed, in
industrialized countries screening policy exists, the
frequency of advanced stages is small compared to that
of precancerous lesions and localized forms. While in
developing countries, cervical cancer is often discovered
at advanced stages due to the lack of screening policy.
Outcomes of locally advanced tumors of cervix are im-
proved since CCRT has become the standard of care for
these stages, based on the report of several randomized
clinical trials and metaanalyses [12]. This therapeutic
modality is superior to RT alone in the rate of local
control, survival without metastatic recurrence, PFS and
OS. In our series, the majority of patients (n = 69.7 %)
received CCRT.
Five year OS of 63.2 % among patients in our series
was much better than that of patients treated in other
part of Africa (sub-Saharan Africa); for example, 2 year
overall survival observed among patients in a recent
Kenyan series was less than 20 % [13]. In addition, the
5 years OS in our study was comparable to that
observed among patients in certain developed countries;
in Canada 5 years survivals varied from 54 to 67 % [14];
in England population, 5-year survival was 69.8 % [15].
In a serie of cervical cancer in young Moroccan
women, treated between 1980 and 1990, overall survival
rate was only 41 % at 5 years [5]. We can conclude that
prognosis of our population has been improved since
the date by introduction of CCRT as a standard treat-
ment of advanced stages.
Five prognostic factors in our study population were
associated with a statistically significant impact (in uni-
variate analysis) on LRRFS, PFS and OS: tumor size,
clinical stage, lymph node involvement, anemia with
hemoglobin lower than 12 g/dl during radiotherapy, and
tumor response to RT (46 Gy). Significant prognostic
factors in multivariate analysis (by Cox proportional
hazard model) include response to RT influencing
significantly PFS and OS, and clinical stage was a factor
influencing LRRFS, PFS and OS. The main prognostic
factors were clinical stage, tumor volume, lymph node
metastases identified by lymphography and grade of
histological differentiation. Clinical stage is clearly the
most powerful determinant of outcome in most scien-
tific papers [16–23].
Conclusions
Cervical cancer is a major health problem in Morocco due
to the high incidence and to the frequent diagnosis at
locally advanced stages. Therefore, the most used strategy
in our center was CCRT. The outcomes of ourpatient has
been improvedas compared to previous published
Moroccan data in the 1990s. Significant prognostic factors
in our study were the stage, and absence of response to
EBRT. To reduce the global burden and mortality of cer-
vical cancer, we should inform and educate women about
risk factors and prevention, so we should start vaccines
(HPV 16–18) to girls before the start of sexual activity and
undertake an effective screening programs for women over
30 years old incorporating validated HPV DNA tests.
Governments are challenged to firstly establish a policy of
systematic screening with the objective of early detection of
cervical cancer, and to obtain an acceptable rate of healing.
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